| Literature DB >> 33787371 |
Lifeng Hu1,2, Jun Fu3, Yonggang Zhou3, Wei Chai3, Guoqiang Zhang3, Libo Hao3, Jiying Chen1,3.
Abstract
OBJECTIVE: This study examined the trends in demographics, the distribution of microorganisms, and antibiotic resistance in patients with periprosthetic joint infection (PJI).Entities:
Keywords: Joint replacement; Staphylococcus; antibiotic resistance; hip; knee; microbiology; periprosthetic joint infection
Mesh:
Substances:
Year: 2021 PMID: 33787371 PMCID: PMC8020254 DOI: 10.1177/03000605211002784
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Patient characteristics.
| 2006–2010 | % | 2011–2015 | % |
| |
|---|---|---|---|---|---|
| Number | 93 | 138 | |||
| Gender | |||||
| Female | 57 | 61.3 | 78 | 56.5 | 0.472 |
| Male | 36 | 38.7 | 60 | 43.5 | |
| Mean age | 60.3 ± 13.4 | 62.5 ± 12.8 | 0.217 | ||
| Arthroplasty site | |||||
| Hip | 55 | 59.1 | 58 | 42.0 | 0.011▲ |
| Knee | 38 | 40.9 | 80 | 58.0 | |
| Comorbidities | |||||
| Hypertension | 22 | 23.7 | 51 | 37.0 | 0.033▲ |
| Diabetes | 18 | 19.4 | 31 | 22.5 | 0.572 |
| IHD | 5 | 5.4 | 21 | 15.2 | 0.021▲ |
| Arrhythmia | 2 | 2.2 | 8 | 5.8 | 0.183 |
| COPD | 1 | 1.1 | 2 | 1.4 | 0.806 |
IHD, ischemic heart disease; COPD, chronic obstructive pulmonary disease.
▲ Significant at P < 0.05.
Microorganisms in patients with periprosthetic joint infection.
| 2006–2010 | 2011–2015 | Total |
| |
|---|---|---|---|---|
| Gram-positive | 67 (66.3) | 94 (62.3) | 161 (63.9) | 0.509 |
| CoNS | 41 (40.6) | 55 (36.4) | 96 (38.1) | 0.505 |
| | 16 (15.8) | 20 (13.2) | 36 (14.3) | 0.565 |
| Streptococci | 3 (3.0) | 11 (7.3) | 14 (5.6) | 0.144 |
| Enterococci | 6 (5.9) | 6 (4.0) | 12 (4.8) | 0.473 |
| Other | 1 (1.0) | 2 (1.3) | 3 (1.2) | 0.811 |
| Gram-negative | 13 (12.9) | 18 (11.9) | 31 (12.3) | 0.822 |
| | 3 (3.0) | 4 (2.6) | 7 (2.8) | 0.879 |
| | 7 (6.9) | 8 (5.3) | 15 (6.0) | 0.592 |
| | 3 (3.0) | 2 (1.3) | 5 (2.0) | 0.360 |
| Other | 0 (0) | 4 (2.6) | 4 (1.6) | 0.100 |
| Fungus | 3 (3.0) | 11 (7.3) | 14 (5.6) | 0.144 |
| Negative | 17 (16.8) | 23 (15.2) | 40 (15.9) | 0.734 |
| Mycobacterium | 1 (1.0) | 5 (3.3) | 6 (2.4) | 0.237 |
| Total | 101 | 151 | 252 |
CoNS, coagulase-negative Staphylococcus.
Polymicrobial infections.
| 2006–2010 | 2011–2015 | |
|---|---|---|
| GPC/GPC | 5 | 6 |
| GPC/GNB | 2 | 5 |
| GNB/GNB | 0 | 1 |
| GPC/FUN | 1 | 1 |
| Total | 8 | 13 |
GPC, gram-positive cocci; GNB, gram-negative bacteria; FUN, fungus.
▲ Significant at P < 0.05.
Antimicrobial resistance of gram-positive bacteria.
| P | OX | CZ | CXM | E | CL | GM | LVX | RA | LNZ | VA | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CoNS | |||||||||||
| 2006–2010 | 34 | 16 | 15 | 4 | 26 | 8 | 5 | 2 | 0 | 0 | 0 |
| (n = 41) | 82.9 | 39.0 | 36.6 | 9.8 | 63.4 | 19.5 | 12.2 | 4.9 | 0 | 0 | 0 |
| 2011–2015 | 22 | 34 | 11 | 12 | 28 | 17 | 15 | 12 | 6 | 0 | 0 |
| (n = 55) | 40.0 | 61.8 | 20.0 | 21.8 | 50.9 | 30.9 | 27.3 | 21.8 | 10.9 | 0 | 0 |
| Total | 56 | 50 | 26 | 16 | 54 | 25 | 20 | 14 | 6 | 0 | 0 |
| (n = 96) | 58.3 | 52.1 | 27.1 | 16.7 | 56.3 | 26.0 | 20.8 | 14.6 | 6.3 | 0 | 0 |
| | 0.01▲ | 0.03▲ | 0.07 | 0.12 | 0.22 | 0.21 | 0.07 | 0.02▲ | 0.08 | – | – |
|
| |||||||||||
| 2006–2010 | 12 | 5 | 2 | 2 | 10 | 8 | 4 | 1 | 0 | 0 | 0 |
| (n =16) | 75.0 | 31.3 | 12.5 | 12.5 | 62.5 | 50.0 | 25.0 | 6.3 | 0 | 0 | 0 |
| 2011–2015 | 6 | 7 | 3 | 3 | 10 | 12 | 10 | 9 | 3 | 0 | 0 |
| (n = 20) | 30.0 | 35.0 | 15.0 | 15.0 | 50.0 | 60.0 | 50.0 | 45.0 | 15.0 | 0 | 0 |
| Total | 18 | 12 | 5 | 5 | 20 | 20 | 14 | 10 | 3 | 0 | 0 |
| (n = 36) | 50.0 | 33.3 | 13.9 | 13.9 | 55.6 | 55.6 | 38.9 | 27.8 | 8.3 | 0 | 0 |
| | 0.01▲ | 0.82 | 0.83 | 0.83 | 0.46 | 0.55 | 0.13 | 0.01▲ | 0.11 | – | – |
P, penicillin; OX, oxacillin; CZ, cefazolin; CXM, cefuroxime; E, erythromycin; CL, clindamycin; GM, gentamicin; LVX, levofloxacin; RA, rifampicin; LNZ, linezolid; VA, vancomycin.
▲ Significant at P < 0.05.
Antimicrobial resistance of gram-negative bacteria.
| GM | CPX | LVX | ATM | C | SCF | TZP | AMC | CARBA | |
|---|---|---|---|---|---|---|---|---|---|
| GNB | |||||||||
| 2006–2010 | 5 | 5 | 3 | 5 | 3 | 5 | 1 | 4 | 0 |
| (n =13) | 38.5 | 38.5 | 23.1 | 38.5 | 23.1 | 38.5 | 7.7 | 30.8 | 0 |
| 2011–2015 | 2 | 7 | 1 | 7 | 12 | 5 | 1 | 9 | 0 |
| (n = 18) | 11.1 | 38.9 | 5.6 | 38.9 | 66.7 | 27.8 | 5.6 | 50.0 | 0 |
| Total | 7 | 12 | 4 | 12 | 15 | 10 | 2 | 13 | 0 |
| (n = 31) | 22.6 | 38.7 | 12.9 | 38.7 | 48.4 | 32.3 | 6.5 | 41.9 | 0 |
|
| 0.077 | 0.981 | 0.158 | 0.981 | 0.018▲ | 0.537 | 0.814 | 0.292 | – |
GNB, gram-negative bacteria; GM, gentamicin; CPX, ciprofloxacin; LVX, levofloxacin; ATM, aztreonam; C, cephalosporin III/IV; SCF, cefoperazone and sulbactam; TZP, piperacillin–tazobactam; AMC, amoxicillin/clavulanic acid; CARBA, carbapenems.
▲ Significant at P < 0.05.